OSI-906 + Erlotinib + Placebo

Phase 2Completed

2 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

NSCLC

Conditions

NSCLC, Non Small Cell Lung Cancer

Trial Timeline

Apr 8, 2011 → Sep 1, 2014

NCT ID

NCT01221077

About OSI-906 + Erlotinib + Placebo

OSI-906 + Erlotinib + Placebo is a phase 2 stage product being developed by Astellas Pharma for NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT01221077. Target conditions include NSCLC, Non Small Cell Lung Cancer.

What happened to similar drugs?

7 of 20 similar drugs in NSCLC were approved

Approved (7) Terminated (3) Active (11)

✅DurvalumabAstraZenecaApproved

✅OsimertinibAstraZenecaApproved

✅GefitinibAstraZenecaApproved

✅Gefitinib + PlaceboAstraZenecaApproved

✅CrizotinibPfizerApproved

✅crizotinibPfizerApproved

✅NivolumabBristol Myers SquibbApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01221077	Phase 2	Completed	Apr 8, 2011	Sep 1, 2014	NSCLC
NCT01186861	Phase 2	Completed	Mar 4, 2011	Mar 11, 2015	Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Competing Products

20 competing products in NSCLC

See all competitors

Product	Company	Stage	Hype Score
Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/Carboplatin	WuXi Biologics	Phase 3	37
Pemetrexed + Erlotinib + Pemetrexed + Erlotinib	Eli Lilly	Phase 2	35
BBP-398 + osimertinib	LianBio	Phase 1	11
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)	BioAtla	Phase 1/2	26
YH42946	Yuhan	Phase 1/2	39
HER3-DXd + HER3-DXd + Osimertinib + Osimertinib + HER3-DXd + HER3-DXd + Osimertinib	Daiichi Sankyo	Phase 1	33
U3-1287 + Erlotinib + Placebo	Daiichi Sankyo	Phase 1/2	32
DS-1205c + Osimertinib	Daiichi Sankyo	Phase 1	21
Datopotamab deruxtecan (Dato-DXd) + Docetaxel	Daiichi Sankyo	Phase 3	47
Datopotamab deruxtecan + Durvalumab + Carboplatin + AZD2936 + MEDI5752 + AZD7789	Daiichi Sankyo	Phase 1	33
Datopotamab deruxtecan + KEYTRUDA® + Carboplatin + Cisplatin	Daiichi Sankyo	Phase 1	33
HER3-DXd (FL-DP) + HER3-DXd (CTM-1 Lyo-DP) + HER3-DXd (CTM-3 Lyo-DP)	Daiichi Sankyo	Phase 1	33
CS-7017 + erlotinib	Daiichi Sankyo	Phase 2	35
gilteritinib	Astellas Pharma	Phase 1	36
OSI-906 + erlotinib + placebo	Astellas Pharma	Phase 2	35
naquotinib + midazolam	Astellas Pharma	Phase 1	29
Exisulind	Astellas Pharma	Phase 1/2	32
naquotinib	Astellas Pharma	Phase 1	21
ASP8273	Astellas Pharma	Phase 2	27
Tarceva	Astellas Pharma	Phase 1	29